Device Advice - issue 29
- PHARMAC will be presenting at three upcoming conferences
- Listings have been announced for orthopaedic implants, single use instruments, interventional radiology products, medical thermometers and non-surgical antimicrobial hand hygiene products
- Two RFPs and one consultation are currently open
- The wound-care market share post-implementation has been released
In this issue
As of 1 July 2018, the Pharmaceutical Schedule includes over 75,000 line items from over 40 suppliers. These contracts cover approximately $180–$190 million of DHB hospital’s annual expenditure on medical devices.
PHARMAC is on track to bring half the intended full scope of hospital medical devices under national contracts before the end of 2018 and the rest by the end of 2019.
In mid-June 2018, PHARMAC staff presented at Healthtech Week in Auckland, and the Cardiac Society of Australia and New Zealand Conference in Christchurch. It was great to see many of you at these events, and feedback from the Christchurch conference suggests our presentation was well-received.
We’re also presenting at the following conferences soon:
- New Zealand Institute of Medical Science Conference in Christchurch on 22 August 2018
- New Zealand Institute of Healthcare Engineering Conference in Napier on 7 – 9 November 2018
- New Zealand Orthopaedic Association Annual Scientific Meeting in Rotorua on 14 – 17 October 2018
The following agreements were completed in June and July 2018, with listings on the Pharmaceutical Schedule from 1 July 2018.
- Interventional radiology products supplied by Endologix New Zealand Co and Device Technologies New Zealand Limited
- Interventional radiology products supplied by Defries Industries New Zealand and Abbott Laboratories NZ Limited
- Medical devices including anaesthesia products, interventional radiology products, medical thermometers and single use instruments, supplied by Intermed Medical Limited
- Non-surgical antimicrobial hand hygiene products supplied by 3M New Zealand Limited and Schülke New Zealand Limited
We have also announced the approval of a listing agreement for interventional radiology products with Endotherapeutics New Zealand Limited, Terumo Australia PTY Limited, and Boston Scientific New Zealand Limited. These products will be listed on the Pharmaceutical Schedule from 1 September 2018, and details will be available on PHARMAC’s website from that date.
Ongoing contracting work
- RFPs have closed for endomechanical and electrosurgical devices, urology, ostomy and continence products, non-invasive ventilation devices, and haemodialysis. We are currently evaluating RFP responses for these categories, which collectively cover $70-80 million in annual expenditure.
- Contracting for hand hygiene, negative pressure wound therapy categories, and VTE prevention devices category is complete, while contracting for medical thermometers is close to completion. Collectively, these categories cover approximately $19 million in annual expenditure.
- Contracting for the interventional radiology category is halfway through the 21 accepted proposals.
- Contracting for orthopaedic implants is ongoing, with 14 contracts completed.
- Consultation is underway seeking feedback on two agreements with EBOS Group Limited (EBOS) and Talgram Health (NZ) Ltd (Talgram). The EBOS Agreement would be the final agreement for the medical thermometer category and the Talgram Agreement would be the first agreement for the needles and syringes category.
Recent RFP releases
- Patient warming and cooling products – closes 24 August 2018.
- Products used in the infusion of fluids into the body – closes 17 August 2018.
Last month, we released the findings of a review we commissioned following the implementation of our first market share agreements for various wound care products used in DHB hospitals.
The review found that, in general, the implementation was managed effectively. Some success factors were identified for PHARMAC, DHBs and suppliers that made implementation effective. While there were minor issues with process, these did not appear to affect the overall success of implementation.
As we continue to expand our devices work, our website will keep you up to date with what’s happening in each category.
You are also welcome to contact us directly at: email@example.com or 04 460 4990. (Note: notifications/consultations are sent from our firstname.lastname@example.org email address – if responding to these, please contact the individual identified in the content, rather than replying to the email.)
You can find the list of medical devices we have contracts for under Section H, Part III of the Pharmaceutical Schedule.
Feel free to circulate this newsletter to anyone you think might be interested.
Feedback on this update
We welcome your feedback on this update. Please let us know what you think via email on email@example.com.
Last updated: 11 February 2019